About Adamas
Overview
Management Team
Board of Directors
Scientific & Clinical Advisors
Investors
Contact Us
Product Pipeline
Pipeline Overview
MDX-8704
ADS-8704
Nurelin™ (ADS-5102)
ADS-8902
Clinical Trials
Partners
Newsroom
Press Releases
Presentations & Publications
Resources
Careers
Job Postings
Benefits
Press Releases
Press Releases
Presentations & Publications
Resources
Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCL Extended Release) Program April 22, 2013
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from its Nurelin™ Program at American Academy of Neurology Conference March 20, 2013
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Disease November 13, 2012
Adamas Pharmaceuticals Presents Update On Nurelin
TM
Program At Cambridge Healthtech Institute’s Parkinson’s Conference June 4, 2012
Click
here
for the Press Release Archive.
© 2013 Adamas Pharmaceuticals, Inc.